newsfilter
← Latest News
GlobeNewswire·

Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

LAVA-1207 in mCRPC continues Phase 1/2a dose escalation study in monotherapy arm and in combination with IL-2Seagen initiated a Phase 1 study of SGN-EGFRd2 (LAVA-1223) to evaluate the safety and tolerability utilizing